Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 08-03 20:40:36时区推断·⟳ 抓取 08-03 20:41:14·⚡ 决策 08-04 10:23:30 +13h42m·84.5 天前
Omeros的YARTEMLEA获CMS新技术附加支付资格，最高每例补偿287,079美元
CMS NTAP最高287,079美元/例直接补给医院，不改变Omeros药品收款价格，但可降低医院使用YARTEMLEA的报销阻力。
📄 原文Investing.com↗ 原文
CMS grants Medicare add-on payment status for TA-TMA treatment
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks SEATTLE - Omeros Corporation (NASDAQ:OMER) anno…
不做 Omeros（OMER.US）
NTAP利好真实但主要降低医院报销摩擦，不直接改变药价；美股已完整交易并收涨6.08%，下一交易日追涨edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- FDA批准YARTEMLEA用于2岁及以上TA-TMA患者，首个该适应症获批疗法。
- 公司披露YARTEMLEA一季度净销售990万美元，J-code自2026年7月生效，并已有CMS附加支付推荐线索。
- 媒体转述公司称CMS授予FY2027 NTAP，10月1日起最高每例额外报销287,079美元。市场反应:OMER当日收涨6.08%至12.56美元。
关键理由
- CMS NTAP最高287,079美元/例直接补给医院，不改变Omeros药品收款价格，但可降低医院使用YARTEMLEA的报销阻力。
- YARTEMLEA一季度净销售约990万美元，面对约9.09亿美元市值，本次增量更偏准入与采用率改善，短期业绩弹性需要后续处方/中心采用验证。
- 事件盘前发布后OMER当日已收涨6.08%，且Q1已披露J-code和CMS推荐附加支付线索，当前盘后再追下一交易日edge不足。
主要风险
- NTAP自2026年10月1日才生效，且支付给医院而非公司，实际放量取决于移植中心诊断、P&T准入和处方采用。
- YARTEMLEA仍处商业化早期，公司未给收入指引，单日上涨后次日继续重定价不确定。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-03-31 · 影响 weakens
内部库仅命中Q4/Q1商业化与报销相关旧线索，未发现足以否定NTAP利好的新增反证；但早期销售和采用率仍需验证。
检索:Omeros YARTEMLEA reimbursement NTAP bearish risk cash debt competition uptake - 做多前查反向 · 来源 web · 日期 2025-12-23 · 影响 weakens
FDA资料显示治疗患者存在严重感染等安全风险，属于标签内风险而非本次新增利空。
检索:YARTEMLEA safety infection risk FDA 原文 ↗
工具调用 · 历史记录,结果未知(5 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- normalize_ticker · 结果未知
- kb_search · 结果未知
- search_case_library · 结果未知
原文全文
展开原文 · 2,084 字
Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
SEATTLE - Omeros Corporation (NASDAQ:OMER) announced that the Centers for Medicare & Medicaid Services has granted New Technology Add-On Payment status for YARTEMLEA (narsoplimab-wuug) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule, according to a press release statement.
Starting October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy will receive up to $287,079 in additional reimbursement per eligible Medicare inpatient. The payments are made to hospitals and do not affect the amount Omeros receives for the drug.
YARTEMLEA is the FDA-approved treatment for TA-TMA, a complication of hematopoietic stem cell transplantation. Approximately 30% of patients undergoing allogeneic HCT in the United States are Medicare beneficiaries.
The NTAP program provides additional reimbursement to eligible hospitals for new technologies before their costs are fully reflected in standard hospital payment rates.
"This additional reimbursement should help ensure that treatment decisions for Medicare patients are guided by clinical need rather than constrained by reimbursement considerations," said Gregory A. Demopulos, chairman and chief executive officer of Omeros.
TA-TMA is a complication of hematopoietic stem cell transplantation in adults and children. Recent studies estimate that TA-TMA develops in up to 56% of allogeneic transplant recipients. Approximately 30,000 allogeneic transplants are performed annually in the U.S. and Europe.
YARTEMLEA is a monoclonal antibody that inhibits mannan-binding lectin-associated serine protease-2, the effector enzyme of the lectin pathway. The drug is approved by the U.S. FDA for the treatment of TA-TMA in adults and children two years of age and older. Omeros is pursuing approval from the European Medicines Agency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SEATTLE - Omeros Corporation (NASDAQ:OMER) announced that the Centers for Medicare & Medicaid Services has granted New Technology Add-On Payment status for YARTEMLEA (narsoplimab-wuug) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule, according to a press release statement.
Starting October 1, 2026, eligible hospitals treating Medicare patients with YARTEMLEA for hematopoietic stem cell transplant-associated thrombotic microangiopathy will receive up to $287,079 in additional reimbursement per eligible Medicare inpatient. The payments are made to hospitals and do not affect the amount Omeros receives for the drug.
YARTEMLEA is the FDA-approved treatment for TA-TMA, a complication of hematopoietic stem cell transplantation. Approximately 30% of patients undergoing allogeneic HCT in the United States are Medicare beneficiaries.
The NTAP program provides additional reimbursement to eligible hospitals for new technologies before their costs are fully reflected in standard hospital payment rates.
"This additional reimbursement should help ensure that treatment decisions for Medicare patients are guided by clinical need rather than constrained by reimbursement considerations," said Gregory A. Demopulos, chairman and chief executive officer of Omeros.
TA-TMA is a complication of hematopoietic stem cell transplantation in adults and children. Recent studies estimate that TA-TMA develops in up to 56% of allogeneic transplant recipients. Approximately 30,000 allogeneic transplants are performed annually in the U.S. and Europe.
YARTEMLEA is a monoclonal antibody that inhibits mannan-binding lectin-associated serine protease-2, the effector enzyme of the lectin pathway. The drug is approved by the U.S. FDA for the treatment of TA-TMA in adults and children two years of age and older. Omeros is pursuing approval from the European Medicines Agency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。